Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 14/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 14/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.61 |
| ▸ | PLK4 | O00444 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.56 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.56 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1944916 | 0.82 | ADORA2B (0.82) | ADORA2BADORA2AADORA3ADORA1PLK4 | |
| SCHEMBL21153826 | 0.82 | ADORA2B (0.78) | ADORA2BADORA2AADORA3ADORA1PLK4 | |
| SCHEMBL1945825 | 0.82 | ADORA2B (1.00) | ADORA2BADORA2AADORA3ADORA1PLK4 | |
| SCHEMBL30012217 | 0.81 | ADORA2B (0.71) | ADORA2BADORA2AADORA3ADORA1PLK4 | |
| SCHEMBL21121166 | 0.81 | ADORA2B (0.75) | ADORA2BADORA2AADORA3ADORA1PLK4 | |
| SCHEMBL242942 | 0.80 | ADORA2B (1.00) | ADORA2BADORA2AADORA3ADORA1PLK4 | |
| SCHEMBL1947163 | 0.80 | ADORA2B (1.00) | ADORA2BADORA2AADORA3ADORA1PLK4 | |
| SCHEMBL1944981 | 0.79 | ADORA2B (1.00) | ADORA2BADORA2AADORA3ADORA1PLK4 | |
| SCHEMBL21121161 | 0.79 | ADORA2B (0.77) | ADORA2BADORA2AADORA3ADORA1PLK4 | |
| SCHEMBL1943564 | 0.78 | ADORA2B (0.83) | ADORA2BADORA2AADORA3ADORA1PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2022-12-22 | — | — | US | disclosed |
| US-20210070764-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2021-03-11 | — | — | US | disclosed |
| WO-2019135259-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADORA2A, ADORA1, ADORA2B | ADORA2B 3/4885ADORA2A 1/4885ADORA3 4/4885 |
| US-20210070764-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADORA2A, ADORA3, ADORA1 | ADORA2B 4/4885ADORA2A 1/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.